4.6 Letter

Response to letter to the Editors-Safety of long-term denosumab therapy

Journal

SUPPORTIVE CARE IN CANCER
Volume 25, Issue 2, Pages 353-355

Publisher

SPRINGER
DOI: 10.1007/s00520-016-3492-8

Keywords

-

Funding

  1. Amgen Inc.

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available